The India cancer biomarkers market was valued at USD 1.25 Billion in 2025, driven by increasing prevalence of cancer across the region. The market is anticipated to grow at a CAGR of 6.00% during the forecast period of 2026-2035, with the values likely to reach USD 2.24 Billion by 2035. With high mortality rates in cancers like breast, cervical, and lung due to late diagnosis, there is an increasing demand for biomarker tests that enable early, accurate detection and personalized treatment strategies.
Base Year
Historical Period
Forecast Period
The ‘Make in India’ initiative is driving the development and launch of locally manufactured, high-precision cancer biomarker kits, reducing dependency on imports and lowering costs for early cancer detection.
Collaborations between Indian diagnostic firms and global technology leaders are facilitating advanced biomarker development and faster regulatory approvals, boosting the market’s technological capabilities.
High tobacco consumption in India fuels the incidence of lung and oral cancers, creating urgent demand for specialized biomarker tests that support early diagnosis and effective management of these tobacco-associated cancers.
Compound Annual Growth Rate
6%
Value in USD Billion
2026-2035
*this image is indicative*
According to ICMR-National Institute of Cancer Prevention and Research, India is witnessing a growing cancer burden, with approximately 2.5 million people currently living with the disease. Each year, over 7 lakh new cancer cases are registered, and around 5.56 lakh cancer-related deaths are reported. The large and growing cancer-affected population creates a significant demand for advanced diagnostic tools. Biomarker-based tests enable early detection, risk assessment, and personalized treatment, which are crucial in improving patient outcomes. Given these factors, the cancer biomarkers market in India is poised for significant growth in the forecast period.
Rise in Government Initiatives to Boost Market Growth
With a strong focus on prevention, early detection, treatment, and innovation, Indian government's is coming up with comprehensive strategies to combat cancer. A press release titled "Towards a Cancer-Free India" revealed that in the Union Budget 2025–26, INR 99,858.56 crore has been allocated to the Ministry of Health and Family Welfare, including INR 3,900.69 crore dedicated specifically to health research. This substantial investment is set to boost cancer diagnostics research, particularly in biomarker discovery and validation, which will drive growth in the cancer biomarkers market. Additionally, the government plans to establish Day Care Cancer Centres in every district hospital, with 200 centers targeted for launch in 2025–26. This move aims to decentralize cancer treatment and improve access to diagnostic services, thereby increasing demand for reliable, efficient biomarker-based testing solutions.
Some of the notable market trends include an emphasis on early diagnosis and personalized treatment to improve patient outcomes and reshape the landscape of cancer diagnostics in the country.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
Market Breakup by Biomarker
Market Breakup by Types of Cancer
Market Breakup by Technology
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region
Breast Cancer and Lung Cancer Hold a Substantial Share Based on Segmentation by Type of Cancer
The cancer biomarkers market in India is primarily driven by the high prevalence and mortality rates of specific cancers, with breast, cervical, lung, and oral cancers accounting for the majority of the disease burden. Breast and cervical cancers dominate among women, with one woman dying of cervical cancer every eight minutes and a 50% mortality rate among newly diagnosed breast cancer cases.
In men, lung and oral cavity cancers are among the leading causes of death, largely due to tobacco use, which causes around 2,500 deaths daily. Lung cancer alone accounts for one in five male deaths. These statistics underscore a strong demand for biomarkers for early detection, diagnosis, and personalized treatment, particularly in breast, cervical, and lung cancers.
The market shows significant regional variation, with the highest growth seen in South and West India due to better healthcare infrastructure, higher awareness, and concentration of advanced diagnostic centers in cities like Bangalore, Chennai, Mumbai, and Pune. South India leads in the adoption of biomarker-based diagnostics, especially for breast and cervical cancers, supported by strong medical research and private healthcare investment. North India, including Delhi NCR and parts of Punjab and Uttar Pradesh, also shows high market potential due to rising cases of lung and oral cancers linked to pollution and tobacco use.
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
F. Hoffmann-La Roche Ltd., headquartered in Basel, Switzerland, was established in 1896. A global leader in pharmaceuticals and diagnostics, Roche plays a significant role in India’s biomarker market through its subsidiary Roche Diagnostics India. The company offers cutting-edge solutions in oncology, cardiology, and infectious disease biomarkers. With a strong emphasis on personalized healthcare, Roche supports early detection and disease monitoring, enhancing clinical outcomes and research across Indian healthcare institutions and laboratories.
Thermo Fisher Scientific Inc., based in Waltham, Massachusetts, USA, was founded in 2006. It is a major player in India’s biomarker landscape, offering a wide array of analytical instruments, reagents, and assay technologies. The company supports biomarker discovery and validation in oncology, neurology, and immunology. Through its India operations, Thermo Fisher collaborates with academic, clinical, and pharmaceutical partners to accelerate precision medicine, enabling high-throughput biomarker analysis and molecular diagnostics across the country.
Headquartered in Abbott Park, Illinois, USA, Abbott Laboratories was founded in 1888. In India, Abbott is a prominent contributor to the biomarker market through its diagnostics division. The company delivers innovative biomarker-based tests and platforms, particularly in cardiology, infectious diseases, and diabetes management. With robust R&D and local collaborations, Abbott helps enhance diagnostic accuracy and timely treatment, strengthening India's healthcare ecosystem with reliable biomarker-driven insights and expanding access to advanced diagnostic solutions.
Illumina, Inc., founded in 1998 and headquartered in San Diego, California, is a global leader in genomics. In India, Illumina plays a pivotal role in advancing the biomarker market through its next-generation sequencing (NGS) technologies. These platforms are instrumental in biomarker discovery, especially in oncology and rare genetic disorders. Illumina partners with research institutions and diagnostic labs across India to enable precision medicine, driving innovations in genetic screening, disease prediction, and personalized treatment strategies.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include QIAGEN N.V., PerkinElmer Inc., Bio-Rad Laboratories, Inc., and Agilent Technologies, Inc., among others.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Biomarker |
|
| Breakup by Type of Cancer |
|
| Breakup by Technology |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share